Skip to main content
BMJ Case Reports logoLink to BMJ Case Reports
. 2018 Jul 13;2018:bcr2018225721. doi: 10.1136/bcr-2018-225721

Port-wine stain as a clue for two rare coexisting entities

Filipa Tavares Almeida 1, Regina Caldas 1, Maria da Luz Duarte 1, Celeste Brito 1
PMCID: PMC6047724  PMID: 30007908

Abstract

Phakomatosis pigmentovascularis (PPV) is an uncommon dermatosis characterised by the presence of both pigmentary and vascular abnormalities.1 Its pathogenesis is not elucidated, and the prognosis is mainly determined by the presence of extracutaneous manifestations, such as Klippel-Trenaunay syndrome (KTS), that is defined by the triad of a port-wine stain (PWS), anomalous veins and progressive overgrowth of the affected extremity. Herein, we report a case of an adult patient, who presented with a large PWS, nevus of Ota, ocular melanosis, and limb hypertrophy and varicosities. These findings represented a rare association of PPV type IIb and KTS.

Keywords: dermatology, ophthalmology

Background

It is important to report cases of phakomatosis pigmentovascularis (PPV) combined with overlapping features of Klippel-Trenaunay syndrome (KTS) for its extreme rarity and prognostic implications, and to elucidate its pathogenesis.

Case presentation

A 40-year-old man presented with diffuse red–purple aggregated patches, confined to the left half of his body. The patient had these asymptomatic cutaneous lesions since birth. Personal history and family history were unremarkable. His parents were non-consanguineous. Physical examination revealed diffuse and extensive red–purple patches on his left half-body, namely upper chest, shoulder, back and limbs, compatible with a port-wine stain (PWS) (figure 1). He also had a slight periorbital diffuse bluish-grey pigmentation and brownish-grey macules on scleral areas (figure 2). The periorbital and scleral pigmentation was consistent with nevus of Ota. These pigmentary lesions combined with the PWS were clinically considered as PPV type II. Furthermore, varicosities and hypertrophy were found on the left limbs, especially on the thigh (figure 3). These findings combined with PWS conducted to clinical diagnosis of KTS.

Figure 1.

Figure 1

Port-wine stain localised on the left half-body (upper chest, shoulder and arm).

Figure 2.

Figure 2

Nevus of Ota and ocular melanosis.

Figure 3.

Figure 3

Port-wine stain associated with varicosities and hypertrophy of the left leg.

Investigations

Laboratory investigation was unremarkable. Chest radiography, abdominal ultrasonography, echocardiogram, venous Doppler ultrasonography and cranial MRI revealed no abnormalities.

At ophthalmological consultation, he was diagnosed with ocular melanosis and annual biomicroscopic follow-up was recommended. No other anomalies were found, including glaucoma.

At neurological assessment, no abnormality was found.

Treatment

Due to the absence of symptomatic or aesthetic concerns, the patient refused the treatment procedures.

Outcome and follow-up

The lesions remained stable for a 1- year period, and the patient was maintained on a multidisciplinary follow-up.

Discussion

PPV is a rare condition defined by the presence of both vascular and melanocytic nevi. Its pathogenesis remains elusive, but both abnormal development of blood vessels and migration of melanocytes during embryogenesis are considered.2 This is thought to result from dysplasia of the vasomotor nerve cells and melanin cells, both of which are derived from the embryonic neural crest.3 Another theory is a genetic phenomenon characterised by loss of heterozygosity, called twin spotting, that is a specific mechanism of somatic mosaicism.4 Twin spots consist of paired patches of mutant tissue that is genetically different from each other and from the heterozygous background tissue.5 It results from vascular and melanotic genetic mutations that occur in each of a pair of homologous chromosomes; consequently, stem cells from the mutant pair origin mixed homologous daughter cells from two different mutations.6 Recently, frequent somatic mutations of GNAQ, a heterodimeric G protein alpha subunit, have been found, both in blue nevus, uveal melanoma and oculodermal melanocytosis and in PWS.7 The findings suggest that clinical manifestations of these conditions can be, in part, caused by activating mutations of GNAQ gene.8

PPV has been classified into four main types according to the pigmentary lesion associated with capillary malformation, classically a PWS. In 2003, a fifth group was described, characterised by cutis marmorata telangiectatica and dermal melanocytosis.9

Each type is further subdivided according to the presence of the cutaneous-only condition (subtype a) or if associated with systemic disease (subtype b).10 In all groups of PPV, it is estimated that half of the patients have systemic manifestations associated, besides skin lesions, the majority of which are ocular, vascular, musculoskeletal and neurological.11 Ophthalmic alterations in PPV include hyperpigmentation of the corneal stroma, conjunctiva, sclera, episclera, iris, trabecular meshwork and choroid. The presence of oculodermal or fundus melanocytosis encompasses a greater risk to develop melanoma. Iris mammillations can also be found, sometimes mimicking Lisch nodules typical of neurofibromatosis type 1.12 Congenital or acquired glaucoma is another condition to be aware, since intraocular pressure is increased due to ocular melanocytosis and nevus flammeus, when it appears in the ocular region.13

PPV type II, also called phakomatosis cesioflammea, consists of PWS and dermal melanocytosis, that in our case was represented by nevus of Ota. Given the additional presence of ocular melanosis and KTS, it was subclassified as PPV type IIb.

KTS is a triad of PWS, venous varicosities and soft tissue or bone hypertrophy. Rarely, concurrence of KTS in PPV has been described in the literature.14 The anomalous venous network present in KTS may be associated with a chronic intravascular coagulopathy and patients are at risk of developing a thromboembolic event.15 Therefore, the evaluation of a patient with PPV should include an appropriate screening for systemic involvement which greatly determines the prognosis of the disease.16 In fact, evolution and prognosis of PPV depend on extracutaneous manifestations, since patients without systemic involvement have a benign course and do not require treatment.17 Regarding ophthalmology, it is important to perform a regular follow-up with a careful fundus examination, due to the higher incidence of choroidal or ciliary body melanoma and glaucoma in patients with PPV.18

Considering the aesthetic impact of skin lesions and to enhance the quality of life of the patients, pulsed laser light can be considered to treat PWS and Q-switched laser for pigmentary nevi.19 Concerning KTS, prophylactic anticoagulation should be considered, especially in patients with evidence of hypercoagulability, when they have additional risk factors for venous thromboembolism, such as surgery, trauma or pregnancy.20

To conclude, the occurrence of PPV with concomitant features of KTS is very rare. It is important to perform a complete clinical and imagiological work-up in patients who present with PPV, in order to identify any underlying condition that may determine the outcome of this disorder.21

Learning points.

  • Phakomatosis pigmentovascularis (PPV) is a rare cutaneous disorder characterised by the presence of both pigmentary and vascular abnormalities.

  • Prognosis of PPV depends largely on its extracutaneous features.

  • Klippel-Trenaunay syndrome, which is defined by the triad of a port-wine stain, anomalous veins and progressive overgrowth of the affected limb, can present with PPV and worsens its prognosis.

Footnotes

Contributors: FTA, RC and CB contributed to the planning, conduction and report of the work. FTA, RC and MdLD contributed to the conception and design of the work. FTA and RC contributed to the acquisition of analysis and interpretation of the results. All authors are responsible for the overall content.

Funding: The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests: None declared.

Patient consent: Obtained.

Provenance and peer review: Not commissioned; externally peer reviewed.

References

  • 1.Okunola P, Ofovwe G, Abiodun M, et al. Phakomatosis pigmentovascularis type IIb in association with external hydrocephalus. BMJ Case Rep 2012;2012:bcr1220115432 10.1136/bcr.12.2011.5432 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Turk BG, Turkmen M, Tuna A, et al. Phakomatosis pigmentovascularis type IIb associated with Klippel-Trénaunay syndrome and congenital triangular alopecia. J Am Acad Dermatol 2011;65:e46–e49. 10.1016/j.jaad.2010.05.025 [DOI] [PubMed] [Google Scholar]
  • 3.Yang Y, Guo X, Xu J, et al. Phakomatosis Pigmentovascularis Associated With Sturge-Weber Syndrome, Ota Nevus, and Congenital Glaucoma. Medicine 2015;94:e1025 10.1097/MD.0000000000001025 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Villarreal DJ, Leal F. Phacomatosis pigmentovascularis of cesioflammea type. An Bras Dermatol 2016;91(5 suppl 1):54–6. 10.1590/abd1806-4841.20164516 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Brittain P, Walsh EJ, Smidt AC. Blotchy baby: a case of phakomatosis pigmentovascularis. J Pediatr 2013;162:1293–1293.e1. 10.1016/j.jpeds.2012.12.040 [DOI] [PubMed] [Google Scholar]
  • 6.Happle R. Phacomatosis pigmentovascularis revisited and reclassified. Arch Dermatol 2005;141:385–8. 10.1001/archderm.141.3.385 [DOI] [PubMed] [Google Scholar]
  • 7.Van Raamsdonk CD, Bezrookove V, Green G, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 2009;457:599–602. 10.1038/nature07586 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Shirley MD, Tang H, Gallione CJ, et al. Sturge-Weber syndrome and port-wine stains caused by somatic mutation in GNAQ. N Engl J Med 2013;368:1971–9. 10.1056/NEJMoa1213507 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Torrelo A, Zambrano A, Happle R. Cutis marmorata telangiectatica congenita and extensive mongolian spots: type 5 phacomatosis pigmentovascularis. Br J Dermatol 2003;148:342–5. 10.1046/j.1365-2133.2003.05118.x [DOI] [PubMed] [Google Scholar]
  • 10.Fernández-Guarino M, Boixeda P, de Las Heras E, et al. Phakomatosis pigmentovascularis: Clinical findings in 15 patients and review of the literature. J Am Acad Dermatol 2008;58:88–93. 10.1016/j.jaad.2007.08.012 [DOI] [PubMed] [Google Scholar]
  • 11.Namiki T, Takahashi M, Nojima K, et al. Phakomatosis pigmentovascularis type IIb: A case with Klippel-Trenáunay syndrome and extensive dermal melanocytosis as nevus of Ota, nevus of Ito and ectopic Mongolian spots. J Dermatol 2017;44:e32–e33. 10.1111/1346-8138.13505 [DOI] [PubMed] [Google Scholar]
  • 12.Abdolrahimzadeh S, Scavella V, Felli L, et al. Ophthalmic Alterations in the Sturge-Weber Syndrome, Klippel-Trenaunay Syndrome, and the Phakomatosis Pigmentovascularis: An Independent Group of Conditions? Biomed Res Int 2015;2015:1–11. 10.1155/2015/786519 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Recupero SM1, Abdolrahimzadeh S, De Dominicis M, Mollo R. Sturge-Weber syndrome associated with naevus of Ota. Eye 1998;12(Pt 2):212–3. [DOI] [PubMed] [Google Scholar]
  • 14.Hall BD, Cadle RG, Morrill-Cornelius SM, et al. Phakomatosis pigmentovascularis: Implications for severity with special reference to Mongolian spots associated with Sturge-Weber and Klippel-Trenaunay syndromes. Am J Med Genet A 2007;143A:945–51. 10.1002/ajmg.a.32327 [DOI] [PubMed] [Google Scholar]
  • 15.Huiras EE, Barnes CJ, Eichenfield LF, et al. Pulmonary thromboembolism associated with Klippel-Trenaunay syndrome. Pediatrics 2005;116:e596–e600. 10.1542/peds.2004-1607 [DOI] [PubMed] [Google Scholar]
  • 16.Finklea LB, Mohr MR, Warthan MM, et al. Two reports of phacomatosis pigmentovascularis type IIb, one in association with Sturge-Weber syndrome and Klippel-Trenaunay syndrome. Pediatr Dermatol 2010;27:303–5. 10.1111/j.1525-1470.2010.01144.x [DOI] [PubMed] [Google Scholar]
  • 17.Viada Peláez MC, Stefano PC, Cirio A, et al. [Phakomatosis pigmentovascularis cesioflammea: a case report]. Arch Argent Pediatr 2018;116:e121–e124. 10.5546/aap.2018.e121 [DOI] [PubMed] [Google Scholar]
  • 18.Shields CL, Di Nicola M, Pellegrini M, et al. Choroidal melanoma in phakomatosis pigmentovascularis with klippel-trenaunay syndrome. Retina 2017:1 10.1097/IAE.0000000000001856 [DOI] [PubMed] [Google Scholar]
  • 19.Segatto MM, Schmitt EU, Hagemann LN, et al. Phacomatosis pigmentovascularis type IIa–case report. An Bras Dermatol 2013;88(6 Suppl 1):85–8. 10.1590/abd1806-4841.20132248 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Redondo P, Aguado L, Marquina M, et al. Angiogenic and prothrombotic markers in extensive slow-flow vascular malformations: implications for antiangiogenic/antithrombotic strategies. Br J Dermatol 2010;162:350–6. 10.1111/j.1365-2133.2009.09513.x [DOI] [PubMed] [Google Scholar]
  • 21.Mandal RK, Ghosh SK, Koley S, et al. Sturge-Weber syndrome in association with Klippel-Trenaunay syndrome and phakomatosis pigmentovascularis type IIb. Indian J Dermatol Venereol Leprol 2014;80:51–3. 10.4103/0378-6323.125507 [DOI] [PubMed] [Google Scholar]

Articles from BMJ Case Reports are provided here courtesy of BMJ Publishing Group

RESOURCES